Results of LCT Parkinsons trial require further analysis
Filed with ASX · · 4 pages · English
Algorae Pharmaceuticals Limited on 6ix
Earlier from Algorae Pharmaceuticals
- LCT files pericyte protective agent provisional patent
- Appendix 4C Quarterly Cash Flow Report 30 September 2017
- Preliminary Final Report and Financial Statements
- NTCELL continues to halt progression of Parkinsons disease
- LCT collaborates with CBR to extend product pipeline
Later from Algorae Pharmaceuticals
- Appendix 4C - Quarterly
- LCT to sell JV Shares and receive DIABECELL licence
- LCT Strategy Update
- NTCELL and Parkinsons trial update
- Preliminary Final Report and 2018 Financial Statements
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals